EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

No Effect of Preoperative Mepolizumab on Early Postoperative Healing After ESS for Severe CRSwNP

A S Homøe iD, M Høxbro iD, J Tidemandsen, V Backer, E Kiaer, S Scott, N Rubek, K Aanæs

Laryngoscope Investigative Otolaryngology · 2026-12 · 11 (6)

DOI: 10.1002/lio2.70619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laryngoscope Investigative Otolaryngology, online erschienen am 29.10.2026. Verfasst von A S Homøe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery and Audiology Copenhagen University Hospital Copenhagen Denmark. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate postoperative endoscopic mucosal healing 2 weeks after ESS in patients with severe CRSwNP treated with surgery alone versus surgery combined with biologics initiated 2 weeks preoperatively.

Methods

In this exploratory post hoc analysis, patients with severe CRSwNP were divided into two cohorts: ESS alone and ESS with preoperative mepolizumab initiated 2 weeks prior to surgery. Postoperative endoscopic video recordings obtained 2 weeks after ESS were anonymized and evaluated by four raters using blinded offline scoring. Healing was assessed using structured endoscopic domains (including discharge, edema, and scarring) and an overall endoscopic visual analogue scale (VAS 0–10). Inter‐rater reliability was assessed.

Results

The overall endoscopic VAS score did not differ between groups. Consistent with this, no differences were observed in endoscopic scores. Inter‐rater agreement was moderate for VAS, discharge, and edema, and low for scarring, reflecting inherent limitations of early postoperative endoscopic assessment.

Conclusion

In this exploratory analysis, preoperative mepolizumab was not associated with measurable differences in early postoperative endoscopic mucosal healing 2 weeks after ESS. These findings relate specifically to early postoperative mucosal appearance and should not be interpreted as evidence regarding the broader efficacy of biologic therapy or longer‐term postoperative outcomes. Larger prospective studies with longer follow‐up are warranted. Level of Evidence 2.

Schlagwörter

Stichwörter der Autor:innen

biologicschronic sinusitis with nasal polypsmepolizumabmonoclonal antibodiespostoperative healingrhinosinusitissinus surgery

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Head and Neck Surgery and Audiology Copenhagen University Hospital Copenhagen Denmark.
  • Department of Clinical Medicine University of Copenhagen Copenhagen Denmark.
  • Rhinoklinikken, Private Hospital Hellerup Denmark.

ORCID-Profile: A S Homøe, M Høxbro

Zitieren

APA

Homøe, A. S., Høxbro, M., Tidemandsen, J., Backer, V., Kiaer, E., Scott, S., Rubek, N., & Aanæs, K. (2026). No Effect of Preoperative Mepolizumab on Early Postoperative Healing After ESS for Severe CRSwNP. Laryngoscope Investigative Otolaryngology, 11(6). https://doi.org/10.1002/lio2.70619

Vancouver

Homøe AS, Høxbro M, Tidemandsen J, Backer V, Kiaer E, Scott S, et al. No Effect of Preoperative Mepolizumab on Early Postoperative Healing After ESS for Severe CRSwNP. Laryngoscope Investigative Otolaryngology. 2026;11(6). doi:10.1002/lio2.70619

BibTeX
@article{Home2026,
  author = {Homøe, A S and Høxbro, M and Tidemandsen, J and Backer, V and Kiaer, E and Scott, S and Rubek, N and Aanæs, K},
  title = {No Effect of Preoperative Mepolizumab on Early Postoperative Healing After ESS for Severe CRSwNP},
  journal = {Laryngoscope Investigative Otolaryngology},
  year = {2026},
  volume = {11},
  number = {6},
  doi = {10.1002/lio2.70619}
}
Kostenlos starten →